Key Highlights
● Revenue was flat while adjusted Earnings rose
● GAAP net loss widened largely on tax
● Annual outlook midpoints were raised
● Nashik pause pushed expected Supply cost above the earlier range
Viatris Inc. (NASDAQ:VTRS), a global healthcare company frequently discussed among value-focused pharmaceutical names, reported third-quarter results that pointed in several directions at once. Total revenues were essentially flat against the prior-year period, adjusted Earnings Per Share and adjusted EBITDA rose, and the net loss under US generally accepted accounting principles widened from a year earlier. Management also raised the midpoints of its annual guidance across every key metric, an outcome that arrived alongside news of a voluntary Manufacturing suspension at its oral solid dose plant in Nashik, India.
The release, filed with the Securities and Exchange Commission as an exhibit attached to a current report, put the central tension in plain view. Supply constraints took a meaningful amount out of quarterly Revenue and are expected to do so again in the fourth quarter. Yet higher-margin businesses and cost discipline lifted profit measures enough for the company to tighten its outlook upward. Interim Chief Financial Officer Paul Campbell described the company as "once again raising the midpoints" of its financial guidance ranges, while Chief Executive Officer Scott A. Smith pointed to "strong execution" and "confidence in the growth trajectory" of the business.
Flat Sales, Richer Mix
Net sales and total revenues were flat on both a reported basis and the operational basis the company also publishes. Beneath that stillness, the mix improved. Adjusted gross Margin widened from the prior-year period, and gross margin under US accounting also moved higher. Adjusted EBITDA grew modestly on a reported basis and slightly on an operational basis, and adjusted earnings per share showed a similar pattern, with reported growth running ahead of operational growth.
Cash generation was the firmer part of the report. Operating Cash Flow rose from the prior-year quarter by a double-digit rate, and free cash flow, both as stated and after excluding transaction and restructuring costs, remained substantial relative to Capital spending. Across the year to date, revenue, adjusted EBITDA and adjusted earnings per share all advanced, with adjusted earnings growing fastest of the group. The year-to-date picture was therefore stronger than the single quarter suggested, helped by a first half in which Greater China and new products contributed strongly.
Why the Paper Loss Widened
The gap between adjusted earnings and the reported loss was one of the most striking features of the quarter. The release attributed the wider net loss primarily to a higher income tax provision, explaining that the company recorded losses in jurisdictions where only minimal tax benefit can be realized. Other items also weighed on the reported figure, including a large charge for purchase accounting amortization, restructuring costs under the program launched this year, Acquisition and divestiture-related costs, a fair-value loss on Biocon shares, and write-offs linked to the earlier fire at Nashik.
Over the year to date the comparison ran the other way. The year-to-date net loss narrowed sharply from the prior-year period, largely because that earlier period carried a substantial Goodwill Impairment that did not repeat. The current period did include a loss within selling, general and administrative expense related to the sale of Tyrvaya product rights, a transaction that a quarterly filing shows was first agreed in August and later amended and restated at the start of October. The company does not issue guidance for net earnings or earnings per share under US accounting, so its raised outlook applies only to adjusted measures, cash flow and revenue.
Nashik Becomes the Bigger Story
The most consequential operational disclosure concerned Nashik. According to the release, the Food and Drug Administration classified its inspection of the Facility as Official Action Indicated in September, following observations issued after a May inspection. In October, "out of an abundance of caution," Viatris voluntarily suspended manufacturing there to concentrate on remediation, and it expects production to resume during the first quarter of next year.
The financial estimate has moved as well. In its second-quarter release, the company had projected a supply-related revenue effect for the entire second half of the year, expressed as a range. The new release assigns a similar amount to each of the third and fourth quarters, and those amounts combined sit above the top of the range given in August. The earlier estimate was made before the regulatory classification and before the voluntary suspension. Management's raised outlook therefore absorbs a larger supply cost than it had previously described.
The plant has been a recurring theme this year. The August release cited a suspension after a fire in February, followed by intermittent disruptions tied to remediation work. Trade publication market data had reported on that fire earlier in the year, when production was halted and a restart was anticipated within a matter of months. Market data also recounted the regulatory history at a separate Viatris site in Indore, India, which received a warning letter and an Import alert from the FDA and cost the company significant revenue. A second Indian site under regulatory scrutiny gives the Nashik classification added weight, although the Indore matter and the Nashik matter are separate proceedings.
A Regional Map With Only One Clear Winner
A quarterly filing breaks the Business into regional segments: Developed Markets, covering mainly North America and Europe; Greater China, covering the mainland, Taiwan and Hong Kong; JANZ, covering Japan, Australia and New Zealand; and Emerging Markets, spanning parts of Asia, the Middle East, South and Central America, Africa and Eastern Europe. Only one of them grew in the third quarter.
Greater China posted double-digit growth on both a reported and an operational basis, though its sales slipped slightly from the level reached in the second quarter and its growth rate cooled from the faster pace of that earlier period. A published transcript of the August Earnings Call shows management warning that a public hospital procurement policy, being implemented province by province, would likely slow hospital-channel growth in the second half, and indicating that a clearer view could emerge around November. The third-quarter release does not offer a provincial breakdown, so the moderation can be observed in the figures without being fully attributed from the release alone.
Developed Markets, by far the largest segment, declined modestly. JANZ and Emerging Markets each fell by mid-single-digit rates or slightly more. The company attributed the overall balance to new product sales, strength in North America and growth in Greater China offsetting supply constraints in Europe and Emerging Markets, along with added competition on certain products.
Old Brands, New Launches and the Generics Squeeze
By category, Brands edged higher while Generics declined. Management linked Brand performance to Greater China and Emerging Markets. Among long-established products, Lipitor, Norvasc and Zoloft all recorded higher net sales than a year earlier, while EpiPen was close to level. Lyrica and Viagra slipped, and the influenza Vaccine Influvac fell by a wider margin. In Generics, launches and growth in certain North American products were not enough to offset supply constraints in Europe and Emerging Markets.
New products remain central to the growth narrative, though the outlook there has become more specific. New product revenue rose from the second quarter's level, and the company now expects a full-year figure that matches the bottom of the range it offered in August. That detail sits quietly beside the raised guidance and suggests the upward revision owes more to margin and cost performance than to a stronger launch contribution. The release itself credits higher-margin businesses and cost discipline for the quarter's results.
Pipeline Events Stacked Into the Autumn
Several regulatory milestones arrived around the report. Gwyn Lo, a low-dose, once-weekly contraceptive patch, launched in the US in October after FDA approval in July. According to market data, the approval rested on a late-stage study and the label is limited to women below a specified body-mass index threshold. The publication quoted Chief Research and Development Officer Philippe Martin describing the product as "a discreet option" for women seeking reversible contraception.
The FDA also approved Ryzumvi, a phentolamine eye drop, for presbyopia in October. According to market data, the preservative-free drop had previously been approved for reversing pharmacologically induced pupil dilation, that it works by reducing pupil diameter without engaging the ciliary muscle, and Opus Genetics developed it while Viatris holds exclusive US commercialization rights. The article gave no launch date or pricing. In Japan, regulators approved Wakix for excessive daytime sleepiness associated with obstructive sleep apnea syndrome and for narcolepsy.
The next near-term event is fast-acting meloxicam, a candidate for moderate-to-severe acute pain. The August release gave a late-December FDA decision date, and the third-quarter release refers to a potential upcoming approval and launch. Further out, the published transcript of the August call shows management expecting late-stage readouts for selatogrel and cenerimod during the first half of next year. Those timelines come from an August discussion and were not restated in the third-quarter release.
Pacira and the Shift Toward Pain Therapies
The largest strategic item is the pending acquisition of Pacira BioSciences (NASDAQ:PCRX), a non-opioid pain therapy company, in an all-cash deal announced in October. Pacira's own filing of the announcement described a tender offer followed by a second-step Merger at the same price, approved unanimously by both boards. It identified Exparel, a long-acting local analgesic for postsurgical pain, and Zilretta, an injection for osteoarthritis knee pain, as the principal products, and said Viatris intended to extend their lifecycles and reach in select markets.
Market data, in a report, said the price represented a large premium to Pacira's last close, that Pacira shares jumped on the news and that Viatris shares fell in morning trading that day. The same report quoted Oppenheimer analyst Les Sulewski calling the premium a "full price," while noting limited antitrust overlap and activist pressure on Pacira since last November. Market commentary framed the deal as part of an effort to build higher-value branded medicines beyond the core generics business.
The timeline has tightened. The October announcement anticipated closing by the end of the year, whereas the third-quarter release now expects completion by the end of November. The quarterly filing shows that the tender offer began at the end of October and is scheduled to expire in mid-November unless extended, with completion dependent on a majority of Pacira shares being tendered and on the expiry of the regulatory waiting period. The annual guidance excludes any Pacira contribution, so the raised outlook is a statement about the existing business.
Balance Sheet Room and Shareholder Returns
Viatris plans to pay for Pacira primarily from excess cash, with the remainder from short-term borrowings, and management continues to expect minimal effect on the gross Leverage Ratio at closing. That ratio stood within the company's stated long-term range at the end of the quarter, toward the lower part of it. Cash and equivalents were higher than at the end of last year, and the August release separately described the sale of the Biocon stake completed in July. Shareholders' Equity declined over the same period.
The company also continued returning capital. The release reported a sizeable year-to-date total returned to shareholders, including share repurchases, and a substantial amount left on the repurchase authorization. The quarterly filing shows that roughly half of the year's repurchases by value occurred in the third quarter, and it records a regular Cash Dividend paid during the period. The filing also lists a new yen-denominated term Loan facility dated July, alongside an existing revolving Credit facility, Commercial Paper program and receivables facility.
Inside the Revised Guidance Table
The revised ranges reward a close reading because the changes were not uniform. For total revenues, the low end rose while the high end came down, producing a narrower range with a slightly higher midpoint. For adjusted EBITDA and adjusted earnings per share, both ends of the range moved up. Free cash flow excluding transaction and restructuring costs followed the same upward pattern. For operating cash flow, the low end rose while the top was unchanged, and expected capital expenditures came down at both ends.
The narrowed revenue range is what might be expected this late in a fiscal year, but the removal of some upper-end revenue potential alongside a higher earnings range underlines where management sees its strength. The guidance also excludes acquired in-process research and development from unsigned deals, the Pacira contribution, and a large expected cash outflow for transaction and restructuring costs. The restructuring program dates to the company's enterprise-wide strategic review. In February, the plan involved cutting a meaningful share of the global workforce over several years, with sizeable charges and targeted annual savings.
Where the Value Debate Sits
Viatris has long attracted attention from valuation-minded observers. Market data published several years ago asked whether the company was a value trap, pointing to low valuation multiples alongside generic competition and limited Patent protection on many products. That framing predates the current strategy, but the underlying debate has persisted in another form: whether a business with established cash flows can shift toward innovative medicines.
A more recent valuation page from market data, using an October share price, showed the company's forward price-to-sales ratio well below both its listed peer average and the wider US pharmaceutical industry average. The page cautioned that the company was unprofitable and that a low price-to-sales ratio can reflect weak margins. Those comparisons rest on the page's own data and model. The latest quarter gives both sides of that discussion fresh material: rising adjusted margins and strong cash flow on one hand, and a wider reported loss, a suspended plant and declining sales in most regions on the other.
Signposts Between Now and Early Next Year
A sequence of dated events now lies ahead. The Pacira tender offer is due to expire in mid-November, and closing is expected before the month ends. The FDA decision date for fast-acting meloxicam falls in late December. Fourth-quarter results will show whether the supply effect tracked the company's estimate, and the first quarter of next year is when manufacturing at Nashik is expected to resume.
None of those outcomes is assured. The release carries the customary forward-looking statements and risk disclosures, and the restart timing depends on a remediation process involving a regulator that has already classified its inspection of the facility as Official Action Indicated. Investors reviewing the report are left with a company whose adjusted profitability improved even as its reported loss widened and its Nashik supply problem grew, and whose next chapter will be shaped substantially by a pain-therapy portfolio it does not yet own.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...